logo-loader
viewTesla Inc

Tesla attracts long bet from Citron short-seller Andrew Left

In a research note, Left acknowledged previously shorting the electric car company, and he's still suing Elon Musk

A Tesla
Citron's change of heart came as Musk and Tesla were hit with another lawsuit

The short-seller Andrew Left is changing his tune on Tesla Inc (NASDAQ:TSLA). His research firm Citron Research called for the electric-car maker’s share price to rebound to $320, a 13% premium on its current value.

Left has been historically critical of Tesla — he’s even suing the company and its embattled CEO Elon Musk over a tweet in which Musk teased the idea of taking the company private. The Securities and Exchange Commission didn’t take kindly to his comments, levying $20 million in fines against Musk and Tesla and forcing the company to put controls in place to oversee Musk’s communications with investors.

READ: Elon Musk and Tesla settle fraud charges with SEC, to pay $40M fine

In a research report published Friday, Left acknowledged being short on the stock for several years, but said the companies' detractors were “over their skis.”

Citron’s reversal comes just as another lawsuit hit Musk and the Tesla board, this time from the law firm Grant & Eisenhofer on behalf of institutional investors Friday morning. The new suit argues that Musk’s tweets have hurt shareholders.

Whether or not Left is right to go long on Tesla, investors were energized regarding the stock, sending its share price up 2.7% to $284.14.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Tesla Inc

Price: 352.17 USD

NASDAQ:TSLA
Market: NASDAQ
Market Cap: $63.48 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Preveceutical announces successful preliminary evaluation of...

Preveceutical (CSE:PREV-OTCQB: PRVCF) President Mak Jawadeker joined Steve Darling from Proactive Vancouver on Skype to discuss the company successfully completing the design, synthesis and preliminary evaluation of key peptides from its scorpion venom-derived peptide research and development...

1 day, 22 hours ago

2 min read